US Pharma Services Market Sizing: Six-Category Overview | Rx Almanac
Investment-grade market sizing across six US pharma services categories spanning the commercialization value chain. Combined, these markets represent approximately $45--47 billion in 2024 US revenu...
Overview
(Source: pharma-services-market-sizing.md)
Summary Table
| # | Category | 2024 US Market Size | 2028E US Market Size | CAGR (2024—2028) | Key Driver |
|---|---|---|---|---|---|
| 1 | Specialty Pharmacy | ~$25B | ~$32—36B | ~7—9% | Pipeline growth; gene/cell therapy; rare disease |
| 2 | Prior Auth & Reimbursement | ~$5B | ~$8.5B | ~14% | CMS-0057 FHIR mandate; AI automation; specialty PA volume |
| 3 | Copay & Financial Assistance | ~$1.0B | ~$1.4B | ~8—10% | Specialty launch volumes; accumulator mitigation; IRA Part D |
| 4 | Market Access Consulting | ~$3.4B | ~$5.0B | ~10% | IRA Medicare negotiation; biosimilar competition; PBM reform |
| 5 | Data Analytics & RWE | ~$8.5B | ~$13.8B | ~13% | FDA RWE framework; value-based contracts; AI/ML integration |
| 6 | Commercial Technology | ~$2.4B | ~$3.4B | ~9—11% | Vault CRM migration; AI/NBA; HCP digital shift |
| Combined | ~$45—47B | ~$64—68B | ~10—12% |
Note: Categories have limited overlap; some revenue adjacencies exist between Cat. 2 (hub services) and Cat. 3 (copay admin), and between Cat. 4 (HEOR consulting) and Cat. 5 (RWE platforms).
1. Specialty Pharmacy Services
Market Definition
Revenue retained by pharmacies from dispensing specialty drugs: dispensing fees and spread revenue, manufacturer hub/service fees ($50—300/patient/month), 340B program margins at health-system pharmacies, specialty generic markups, and clinical management fees. Excludes the $265B in gross specialty drug dispensing revenues (primarily drug cost pass-through) — the focus is the pharmacy gross profit layer above drug acquisition cost.
Market Size
| Year | Pharmacy-Dispensed Specialty Revenue | Services/Gross Profit Revenue |
|---|---|---|
| 2024 | ~$265B | ~$22—28B |
| 2025E | ~$286—292B | ~$27—28B |
| 2026E | ~$309—321B | ~$29—30B |
| 2028E | ~$360—388B | ~$32—36B |
Implied services CAGR (2024—2028): ~7—9%
Sub-segment breakdown by channel:
| Channel | Share of Specialty Dispensing (2024) | Services Revenue Margin |
|---|---|---|
| PBM-Affiliated (Accredo, OptumRx, Caremark) | ~65—67% | 4—6% branded; 15—25%+ generics |
| Walgreens Specialty | ~9—10% | 3—5% blended |
| Health System—Owned | ~8—10% | Variable; 340B margin 20—50% on eligible volume |
| Independent/Boutique (PANTHERx, Orsini, Biologics) | ~7—10% | 8—15%+; exclusive network premium |
| Health Plan—Owned (CarelonRx, CenterWell) | ~4—6% | 4—7% |
Top 5 Players by Market Share
| Rank | Company | Est. Dispensing Revenue | Est. Market Share | Est. Services Revenue |
|---|---|---|---|---|
| 1 | CVS Health (CVS Specialty / Caremark) | ~$75—80B | ~28—30% | ~$3—5B |
| 2 | Cigna/Evernorth (Accredo / Express Scripts) | ~$60—70B | ~22—26% | ~$2.5—4B |
| 3 | UnitedHealth/Optum (OptumRx Specialty) | ~$45—55B | ~17—21% | ~$2—3.5B |
| 4 | Walgreens Specialty Pharmacy | ~$24B | ~9—10% | ~$0.8—1.2B |
| 5 | PANTHERx Rare (independent) | ~$3.6B | ~1.5% | ~$0.3—0.5B |
Top 3 combined share: ~65—67%.
Growth Drivers
- Specialty pipeline acceleration. ~75% of ~7,000 pipeline drugs are specialty medicines; IQVIA projects 55%+ of US drug spending by 2028.
- Gene and cell therapy emergence. Ultra-complex therapies (CAR-T, gene replacement) command highest per-prescription service fees; Walgreens built dedicated 18,000 sq. ft. Gene & Cell Services Pharmacy in Pittsburgh.
- Health system channel expansion. Health system—owned specialty pharmacies grew from 15% to 27% of accredited locations (2017—2024).
- Rare/orphan drug growth. Orphan drugs projected at 20% of prescription drug sales by 2026.
- Biosimilar volume expansion. 68 FDA-approved biosimilars through 2024; compresses per-unit margins but expands patient volume.
Risks / Headwinds
- Biosimilar adoption and specialty generic proliferation compressing margins on blockbusters (Humira, Stelara, Enbrel, Keytruda).
- PBM reform and regulatory pressure on spread pricing (FTC found Big 3 earned $7.3B from specialty generic markups 2017—2021).
- DIR fee compression: up 46.8% from 2020 to 2022, totaling $9.5B.
Recent M&A
| Year | Transaction | Value |
|---|---|---|
| 2025 | Cencora acquires OneOncology | $7.4B |
| 2025 | Walgreens taken private by Sycamore Partners | ~$23.7B enterprise |
| 2024 | Cardinal Health acquires Solaris Health | $1.9B |
| 2024 | Cardinal Health acquires Integrated Oncology Network | $1.12B |
| 2024 | BrightSpring IPO (KKR exit) | ~$1B IPO |
2. Prior Authorization & Reimbursement Support
Market Definition
Technology platforms, AI automation tools, and outsourced services for managing end-to-end prior authorization: ePA networks, AI-powered PA automation, utilization management outsourcing, pharma hub/patient access services, and embedded RCM PA modules. The $35B figure frequently cited by Health Affairs represents total admin cost burden — not vendor revenue.
Market Size
| Segment | 2024 US Revenue | 2028E US Revenue | CAGR |
|---|---|---|---|
| Technology Platforms (SaaS/ePA) | ~$1.1B | ~$2.0—2.3B | ~16—20% |
| Service Providers (Outsourced PA / Hub) | ~$4.0B | ~$6.0—6.5B | ~11—13% |
| AI-Powered PA Startups | ~$0.1—0.15B | ~$0.6—1.0B | ~50%+ |
| Total US Market | ~$5.0B | ~$8.5B | ~14% |
Only 31% of medical PA transactions are fully electronic (2023 CAQH Index), indicating substantial conversion opportunity.
Top 5 Players by Market Share
| Rank | Company | Segment | Est. US Revenue | Est. Market Share |
|---|---|---|---|---|
| 1 | EviCore (Evernorth/Cigna) | UM/PA Outsourcing | ~$2.0B | ~35—40% |
| 2 | CoverMyMeds/RxTS (McKesson) | ePA Network + Mfr Services | ~$600—900M | ~12—18% |
| 3 | Surescripts | ePA Infrastructure | ~$200—400M | ~4—8% |
| 4 | Lash Group (Cencora) | Pharma Hub / Patient Access | ~$400—600M | ~8—12% |
| 5 | AssistRx (WCAS) | Specialty Hub / Therapy Initiation | ~$119M | ~2—3% |
Growth Drivers
- CMS-0057-F mandates FHIR-based PA APIs at all impacted payers by January 2027, forcing procurement across 3,800+ organizations.
- AI automation: manual PA costs ~$14.49/tx vs. ~$5.84 electronic; AI can automate 50—75% of manual tasks.
- Specialty PA volume explosion: Medicare Advantage payers processed ~53M PA requests in 2024 (up from 46M in 2022).
- Surescripts achieved 18-second median PA approval across 76,000+ prescribers by October 2025.
Risks / Headwinds
- Regulatory reform paradox: 10+ states passed PA reform in 2024; gold-carding could reduce PA volume structurally.
- 70% of PA communications remain via fax/phone as of early 2026.
- Change Healthcare ransomware attack (Feb 2024) highlighted systemic fragility.
Recent M&A / Funding
| Date | Transaction | Value |
|---|---|---|
| Jun 2025 | Tennr Series C (IVP / a16z) | $101M ($605M val.) |
| May 2025 | Cohere Health Series C (Temasek) | $90M ($200M total) |
| Oct 2024 | Infinitus Systems Series C (a16z) | $51.5M ($102.9M total) |
| Feb 2024 | WCAS acquires AssistRx | ~$600M valuation |
3. Copay & Financial Assistance Programs
Market Definition
Revenue earned by third-party vendors administering manufacturer-funded financial assistance: copay card/e-voucher administration, PAP management, bridge/quick-start programs, accumulator/maximizer mitigation analytics, and pharma-segment prepaid card delivery. Excludes the ~$21.4B in gross copay spending itself.
Market Size
| Sub-Segment | 2024 US Revenue |
|---|---|
| Copay card / e-voucher administration | $400—500M |
| PAP management & free goods services | $150—200M |
| Bridge / quick-start program admin | $75—100M |
| Accumulator/maximizer mitigation | $50—100M |
| Prepaid debit card delivery (pharma) | $30—50M |
| Total US Market | ~$950M—$1.1B (mid: ~$1.0B) |
| Scenario | 2024 | CAGR | 2028E |
|---|---|---|---|
| Base Case | ~$1.0B | 8—10% | ~$1.4B |
| Bull Case | ~$1.0B | 11—13% | ~$1.6B |
| Bear Case | ~$1.0B | 5—6% | ~$1.2B |
Top 5 Players by Market Share
| Rank | Company | Est. 2024 Revenue | Est. Market Share | Ownership |
|---|---|---|---|---|
| 1 | ConnectiveRx | ~$240—310M | ~27—32% | Genstar Capital (PE) |
| 2 | Lash Group (Cencora) | ~$100—150M | ~11—16% | Public (NYSE: COR) |
| 3 | TrialCard | ~$80—120M | ~9—12% | PE-backed |
| 4 | CareMetx | ~$60—100M | ~7—10% | General Atlantic |
| 5 | Paysign (PAYS) | $12.65M (FY2024) | ~1.5—3.5% | Public (NASDAQ: PAYS) |
ConnectiveRx leads with 150+ pharma clients. Paysign showed 214.5% YoY pharma revenue growth in FY2024.
Growth Drivers
- Specialty pipeline: 400—500+ specialty agents in late-stage, each launching with 3—10 year copay programs.
- Gross-to-net bubble: reached $356B in 2024, intensifying manufacturer pressure for copay program sophistication.
- Accumulator/maximizer mitigation: $6.9B of $21.4B diverted (37% of total copay value) in 2024; 84% of commercially insured lives in accumulator-available plans.
- IRA Part D changes: $2,000 OOP cap drives program restructuring mandates.
Risks / Headwinds
- IRA drug price negotiation may reduce specialty pricing, lessening copay program necessity.
- Regulatory uncertainty on accumulators (25 states + DC enacted bans covering ~17% of commercial lives; ERISA plans unprotected).
- PBM disintermediation: CVS PrudentRx and Express Scripts SaveOnSP position Big 3 as competitors.
Recent M&A
| Date | Transaction | Significance |
|---|---|---|
| Aug 2025 | EVERSANA + Waltz Health merger | Pharma commercialization + drug access platform |
| May 2025 | PharmaCord + Mercalis → Valeris (Permira) | ~3,000+ employee independent patient access platform |
| Feb 2024 | WCAS acquires AssistRx | ~$600M valuation |
4. Market Access Consulting
Market Definition
US consulting services sold to pharma manufacturers: payer strategy and formulary access, pricing and reimbursement strategy, HEOR, market access launch planning, payer engagement, and government affairs/policy consulting. Excludes hub/patient services, CRO-executed HEOR, standalone regulatory, and enterprise strategy consulting not primarily market-access focused.
Market Size
| Sub-Segment | 2024 US Revenue |
|---|---|
| Pricing & reimbursement strategy | ~$900M |
| HEOR consulting | ~$820M |
| Payer strategy & formulary access | ~$750M |
| Launch market access planning | ~$600M |
| Government affairs & policy consulting | ~$350M |
| Total | ~$3.4B |
| Year | US Market | Notes |
|---|---|---|
| 2024 | $3.4B | Central estimate |
| 2026E | $4.1B | IRA price negotiation compliance peak |
| 2028E | $5.0B | ~10% CAGR |
Highly fragmented: top 5 hold ~15—20% combined share; 200+ boutiques fill the remainder.
Top 5 Players by Market Share
| Rank | Company | Est. US MA Consulting Revenue | Est. Market Share |
|---|---|---|---|
| 1 | Precision AQ | ~$185—210M | ~5.5—6.5% |
| 2 | Xcenda (Cencora) | ~$120—140M | ~3.5—4.5% |
| 3 | Trinity Life Sciences (Kohlberg PE) | ~$80—120M | ~2.5—3.5% |
| 4 | ZS Associates (Value & Access) | ~$100—165M | ~2.5—3.5% |
| 5 | Avalere Health (Bridgepoint PE) | ~$80—100M | ~2.5—3.0% |
Growth Drivers
- IRA Medicare Drug Price Negotiation: reductions of 38—79% on first 10 drugs; 20+ drugs/year entering negotiation by 2028.
- Specialty launch complexity: average first-year launch revenues fell from $140M (2018) to $60M (2022).
- RWE as regulatory/payer currency: FDA 2024 RWE guidance and CMS use in IRA negotiations.
- PBM reform: 2026 Consolidated Appropriations Act requires 100% rebate pass-through in Medicare Part D.
Risks / Headwinds
- IRA policy uncertainty and pipeline rationalization reducing total consulting engagements.
- Insourcing by large pharma (internal HEOR teams) and AI displacement of commodity deliverables.
Recent M&A
| Date | Target | Acquirer |
|---|---|---|
| Nov 2025 | EVERSANA APACME Advisory | Trinity Life Sciences |
| Aug 2024 | PHAR (HTA/HEOR) | ADVI Health (Sheridan Capital) |
| Jun 2024 | Mtech Access + Delta Hat | Petauri Health (Oak Hill) |
| 2022 | Multiple firms → Lumanity | Arsenal Capital Partners ($106.9M rev by 2022) |
5. Data Analytics & Real-World Evidence
Market Definition
Pharma-specific data platforms and subscriptions (licensed claims, patient-level, prescriber, formulary data), RWE generation services, commercial analytics platforms (SaaS for sales force effectiveness, launch tracking, market share), GTN/channel analytics, and AI-powered analytics layers sold to life sciences companies. Excludes general healthcare IT, payer actuarial analytics, and non-pharma hospital analytics.
Market Size
| Segment | 2024 US Revenue |
|---|---|
| IQVIA TAS (US-attributable) | ~$2.8—3.0B |
| Veeva Commercial Data (Compass Suite) | ~$0.45—0.55B |
| Symphony Health (ICON) | ~$0.20B |
| Komodo Health | ~$0.25—0.35B |
| ConcertAI | ~$0.15—0.20B |
| IntegriChain | ~$0.12—0.15B |
| Other (Flatiron, HealthVerity, Aetion, OM1, TriNetX, Claritas) | ~$0.5—1.0B |
| Total | ~$8.0—9.5B (mid: $8.5B) |
| Year | US Market |
|---|---|
| 2024 | ~$8.5B |
| 2026E | ~$10.8B |
| 2028E | ~$13.8B (13% CAGR) |
RWE specifically: ~$1.8—2.2B US in 2024, growing to ~$3.5B by 2028 at 14.8% CAGR.
Top 5 Players by Market Share
| Rank | Company | Est. US Revenue (2024) | Est. US Share |
|---|---|---|---|
| 1 | IQVIA (TAS segment) | ~$2.8—3.0B | ~33—35% |
| 2 | Veeva Systems (Commercial) | ~$0.45—0.55B | ~5—7% |
| 3 | Komodo Health | ~$0.25—0.35B | ~3—4% |
| 4 | ConcertAI | ~$0.15—0.20B | ~2—3% |
| 5 | IntegriChain | ~$0.12—0.15B | ~1.5—2% |
IQVIA dominates with ~33—35% share. Veeva Compass Suite (launched Jan 2024) is the primary competitive threat.
Growth Drivers
- FDA RWE framework: 2024 guidance enables EHR and claims data for approvals and label expansions.
- Value-based contracting: 58%+ of US payers had at least one OBC as of 2022; cell/gene pricing accelerates adoption.
- AI/ML integration: Komodo Marmot, ConcertAI CARAai, IQVIA Connected Intelligence reduce time-to-insight from weeks to minutes.
- Specialty/rare disease complexity: patient-finding, channel analytics, SP data, and post-market RWE mandates under accelerated approval.
Risks / Headwinds
- Data privacy regulation (CPRA, state health data protection acts) creating compliance complexity.
- Veeva/IQVIA price competition compressing data licensing pricing industry-wide.
- Pharma budget sensitivity to IRA revenue pressure (IQVIA TAS growth slowed to ~1% in Q1 2024 before recovering).
Recent M&A
| Date | Transaction |
|---|---|
| Jan 2024 | Veeva Compass Suite full commercial launch |
| Nov 2023 | Nordic Capital majority stake in IntegriChain |
| Jun 2024 | IntegriChain acquires BridgeView Data |
| May 2025 | Komodo Health—Nasdaq Medical Claims Insights partnership |
6. Pharma Commercial Technology
Market Definition
Pure SaaS and software + services platforms for pharma/biotech commercial functions: CRM and field force automation, omnichannel engagement, commercial analytics and AI/NBA, HCP master data and commercial data products, and revenue management/compliance software. Excludes Veeva Vault R&D/regulatory, CRO services, pharmacovigilance, and patient services/hub platforms.
Market Size
| Sub-Segment | 2024E US | 2028E US | CAGR |
|---|---|---|---|
| CRM / Field Force | ~$820M | ~$1,120—1,200M | 8—10% |
| Omnichannel Engagement | ~$550M | ~$800—870M | 10—12% |
| Revenue Management | ~$165M | ~$210—225M | 6—8% |
| AI / Commercial Analytics | ~$250M | ~$435—520M | 15—20% |
| Commercial Data Products | ~$550M | ~$750—810M | 8—10% |
| Total | ~$2.35B | ~$3.3—3.6B | ~9—11% |
Top 5 Players by Market Share
| Rank | Player | Est. US Revenue (2024) | Est. US Share |
|---|---|---|---|
| 1 | Veeva Systems (Pure SaaS + data) | $700—800M | ~30—35% |
| 2 | IQVIA (TAS commercial portion) | $250—350M | ~10—15% |
| 3 | Model N (Vista Equity) | $150—180M | ~6—8% |
| 4 | Salesforce (Life Sciences Cloud) | $50—100M | ~2—4% |
| 5 | Aktana / PharmaForceIQ | $40—70M | ~2—3% |
Veeva holds ~80% global CRM market share with 1,500+ customers. Top 3 control ~50—55% of total market.
Growth Drivers
- Vault CRM migration upsell (2025—2029): mandatory migration creates ACV expansion; 125+ customers live by March 2026.
- AI/NBA becoming mandatory: 30—40% HCP engagement improvement and 4—10% sales lift.
- Specialty launch complexity: 63+ NMEs approved in 2024; cell/gene requires personalized HCP engagement.
- IRA reporting and 340B complexity driving Model N adoption.
Risks / Headwinds
- IRA pricing pressure compressing drug revenues and commercial budgets; $200B patent cliff 2024—2028.
- Salesforce LSC + IQVIA partnership creating credible second platform; OCE sunset by 2029.
- Vault CRM execution risk with concentrated migration timeline.
Recent M&A / Strategic Shifts
| Date | Event |
|---|---|
| Jan 2026 | Aktana acquired by PharmaForceIQ (first “optichannel-in-a-box” specialist) |
| Oct 2025 | Salesforce LSC general availability (70+ customers incl. Pfizer, Takeda) |
| Apr 2024 | IQVIA—Salesforce expanded partnership; OCE licensed to Salesforce |
| Apr 2024 | Model N taken private by Vista Equity ($1.25B; ~4.8x forward revenue) |
Cross-Category Themes
1. The IRA as Dominant Structural Catalyst
The IRA reshapes all six categories simultaneously. Market access consulting sees the most direct demand surge; commercial technology faces the sharpest headwind from compressed drug revenues; specialty pharmacy faces dispensing margin compression. The IRA is simultaneously the sector’s largest growth driver and primary cost pressure.
2. Vertical Integration and Platform Consolidation
PBMs integrating into specialty pharmacy (CVS/Caremark, Evernorth/Accredo), PA outsourcing (EviCore), and copay administration (PrudentRx, SaveOnSP). PE sponsors (Arsenal/Lumanity, Kohlberg/Trinity, Permira/Valeris) building scale platforms. CRM consolidating to two platforms (Veeva Vault CRM vs. Salesforce LSC/IQVIA).
3. AI as Both Opportunity and Disruptor
Asymmetric effects: PA voice AI at 50%+ CAGR (new revenue); commercial AI/NBA at 15—20% CAGR (mandatory infrastructure); RWE AI reduces time-to-insight (platform stickiness); consulting AI automates commodity work (margin compression). Winners have proprietary data moats.
4. Specialty Drug Complexity as Universal Tailwind
~75% of ~7,000 pipeline drugs are specialty; projected 55%+ of US spending by 2028. Each launch requires all six service categories. The specialty pipeline is the universal demand engine.
5. Regulatory Complexity as Sustainable Demand Generator
CMS-0057-F FHIR mandate (3,800+ payer procurement wave), PBM reform (2026 CAA), FDA RWE guidance, increasing UM — regulatory complexity accumulates, creating durable recurring demand.
6. Private Equity as Market Architect
PE capital reshaping market access consulting, copay administration, and commercial technology. Entry multiples of 10—15x EBITDA reflect conviction in recurring revenue — especially platforms with embedded compliance or proprietary data assets.
Ingested from pharma-services-market-sizing.md. Report compiled April 2026. All estimates represent analytical synthesis of public filings, industry research, and sector-specific data; they are not audited figures.